BOLT BIOTHERAPEUTICS INC(NASDAQ:BOLT) stock News

BOLT Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Benzinga - Mentions: IVA ENGN RLMD CMND ...

12 Health Care Stocks Moving In Thursday's After-Market Session

3 days ago - By: Benzinga - Mentions: NBY EPIX RMTI ELMD ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

16 days ago - By: Zacks Investment Research - Mentions: ELMD

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

16 days ago - By: The Motley Fool

Bolt Revenue Jumps 39 Percent in Q2

16 days ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

16 days ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

23 days ago - By: Zacks Investment Research - Mentions: PHAT

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: IMNM

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: ARCT

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Yahoo Finance - Mentions: KRYS JAZZ HEPA TECH

Biotech Alert: Searches spiking for these stocks today

4 months ago - By: Zacks Investment Research - Mentions: PRTA

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

4 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

4 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

4 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

5 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

5 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

5 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

5 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

6 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Participate in Upcoming March Conferences

7 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

7 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

10 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

10 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

10 months ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

a year ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces Changes to its Board of Directors

a year ago - By: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces Changes to its Board of Directors

a year ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

a year ago - By: The Schall Law Firm

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

a year ago - By: The Schall Law Firm

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

a year ago - By: Rosen Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

a year ago - By: Schall Law

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

a year ago - By: Faruqi & Faruqi, LLP

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

a year ago - By: Bragar Eagel & Squire - Mentions: CVS WBA ICU

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

a year ago - By: THE ROSEN LAW FIRM, P. A.

BOLT BIOTHERAPEUTICS INC (BOLT) Stock News

BOLT Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Bolt Revenue Jumps 39 Percent in Q2

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Biotech Alert: Searches spiking for these stocks today

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics Announces Changes to its Board of Directors

Bolt Biotherapeutics Announces Changes to its Board of Directors

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit